Therefore, pharmacological inhibition of the Gα12-ROCK1 axis may represent a promising strategy for the treatment of liver diseases including acute liver injury, hepatitis, and fibrosis/cirrhosis. This evidence concerns the gene ROCK1 and hepatitis A virus infection.